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Abstract 
Higher Levels of Stress Are Associated with a Significant Symptom Burden in Oncology 
Outpatients Receiving Chemotherapy 
by Katarina Jakovljevic  
Background: A cancer diagnosis and associated treatments, as well as the uncertainty of the 
disease course, are stressful experiences for most patients. However, little information is 
available on the relationship between stress and symptom burden. The study purpose was to 
evaluate for differences in the severity of fatigue, lack of energy, sleep disturbance, and 
cognitive function, among three groups of patients with distinct stress profiles.  
Methods: Patients receiving chemotherapy (n=957) completed measures of general, cancer 
specific, and cumulative life stress and symptom inventories. Latent profile analysis was used to 
identify subgroups of patients with distinct stress profiles.  
Results: Three distinct subgroups of patients were identified (i.e., Stressed (39.3%), Normative 
(54.3%), Resilient (5.7%)). For cognitive function, significant differences were found among the 
latent classes (Stressed<Normative<Resilient). For both sleep disturbance and morning and 
evening fatigue, compared to the Normative and Resilient classes, the Stressed class reported 
higher severity scores. Compared to the Normative and Resilient classes, the Stressed class 
reported low levels of morning energy. Compared to the Normative class, the Stressed class 
reported lower levels of evening energy.  
Conclusions: Consistent with our a priori hypothesis, patients in the Stressed class had the 
highest symptom severity scores for all four symptoms and all of these scores were above the 
clinically meaningful cutoffs for the various instruments.   
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Introduction 
A cancer diagnosis, its related treatments, and the uncertainty of the disease course are 
stressful experiences for most patients1, 2 that can have acute and chronic effects.3 Stress is an 
adaptive response that activates the sympathetic and parasympathetic nervous systems as well as 
the hypothalamic-pituitary-adrenal (HPA) axis.4 While the types and the duration of stressors 
vary greatly, equally important is the significant amount of variability in individuals’ cognitive, 
emotional, and neurobiological responses to stress.5 A growing body of preclinical and clinical 
evidence, summarized below, suggests that these inter-individual differences in oncology 
patients’ responses to stress may contribute to the occurrence and severity of common physical 
symptoms (i.e., fatigue, sleep disturbance, deficits in energy levels, cognitive impairment) 
associated with the receipt of chemotherapy (CTX). 
Fatigue occurs in up to 90% of patients undergoing CTX.6 In the general population, 
fatigue is an adaptive response to acute stress that assists an individual to conserve energy and 
maintain homeostasis. In situations of chronic stress or cumulative exposure to stressful life 
events, the sympathetic nervous system (SNS), parasympathetic nervous system (PNS), and HPA 
axis experience an increased allostatic load which results in increases in fatigue severity.7 In 
terms of oncology patients, in a recent review,2 the authors hypothesized that stress-induced 
increases in inflammatory responses were an underlying mechanism for fatigue. However, only 
one study was identified that evaluated for associations between fatigue severity and stress in 
oncology patients receiving CTX. In this study, that used latent profile analysis (LPA) to identify 
subgroups of patients with distinct morning and evening fatigue profiles,8 higher levels of 
general and disease-specific stress were reported by patients in the highest morning and evening 
fatigue subgroups. 
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Sleep disturbance is reported by 30% to 88% of oncology patients and has a significant 
impact on patients’ mood, functional status, and quality of life.9, 10 As noted in two recent 
reviews,3, 11 findings from several animal and human studies suggest that stress can have an 
impact on the sleep-wake cycle in a variety of ways depending primarily on the types of stressors 
experienced, the duration of exposure (i.e., acute versus chronic stress), and inter-individual 
responses to stress. However, research on the association between sleep disturbance and stress in 
oncology patients in extremely limited. In the only study identified,12 that evaluated twenty-nine 
newly diagnosed patients with breast cancer and co-occurring insomnia, while no measure of 
stress was used, patients with insomnia prior to their cancer diagnosis reported high cognitive 
pre-sleep arousal scores (i.e., a proxy measure of stress). 
Cancer-related cognitive impairment (CRCI) is highly prevalent with up to 75% of 
patients reporting decrements in cognition during CTX.13 In an excellent review,14 Datta and 
Arnsten describe the influences of chronic stress on the functioning of the prefrontal cortex 
(PFC). Findings across studies suggest that this area of the brain, that controls behaviors, 
thoughts, and emotions, when exposed to chronic stress exhibits changes in connectivity and 
neuronal atrophy. It is interesting to note that in a recent magnetic resonance imaging (MRI) 
study of forty patients with breast cancer,15 CRCI was associated with changes in functional 
connectivity in the PFC. In addition, findings from a systematic review suggest that psychosocial 
factors, including increased stress, are associated with CRCI.16 Finally, in a study of patients 
undergoing CTX,17 higher levels of CRCI were associated with higher levels of general and 
disease specific stress. 
Given the high levels of stress that oncology patients experience; the growing preclinical 
evidence, as well as evidence from the general population, on the associations between stress and 
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common physical symptoms; and the paucity of research on these associations in oncology 
patients, in this study we extend our previous work on stress in oncology patients. This study is a 
logical extension of our previous report that identified distinct stress profiles in a large sample of 
oncology patients undergoing CTX (n=957).18 In brief, we used LPA to identify subgroups of 
patients based on their concurrent evaluations of global (i.e. Perceived Stress Scale 19) and 
cancer-specific stress (i.e., Impact of Event Scale-Revised 20), lifetime stress exposure (i.e., Life 
Stressor Checklist-Revised 21), and resilience (i.e., Connor-Davidson Resilience Scale 22). Three 
subgroups of patients with distinct stress profiles were identified (Table 1). The first group, 
labeled “Normative” (54.3%), was characterized by intermediate levels of global stress and 
resilience, lower levels of cancer-related stress, and the lowest amount of cumulative life stress. 
The second group, labeled “Stressed” (39.3%) reported the highest levels of global and cancer 
specific stress, the lowest resilience scores, and the most life stress. The third group, labeled 
“Resilient” (5.7%) had the lowest global stress scores, levels of cancer-specific stress that were 
comparable to the “normative” group, the highest resilience scores, and intermediate levels of 
cumulative life stress. The purpose of this study was to evaluate for differences in the severity of 
fatigue, lack of energy, sleep disturbance, and cognitive function, among these three stress 
groups. We hypothesized that compared to patients in the other two groups, patients in the 
“stressed” group would have the highest physical symptom severity scores. 
Methods 
Patients and Settings 
This analysis used data from a descriptive, longitudinal study that evaluated the symptom 
experience of oncology outpatients receiving CTX.23 Eligibility criteria included: ≥18 years of 
age; diagnosis of breast, gastrointestinal, gynecological, or lung cancer; received CTX within the 
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preceding four weeks and scheduled to receive two additional cycles; and able to read, write, and 
understand English. Recruitment occurred at two Comprehensive Cancer Centers, one Veteran’s 
Affairs hospital, and four community-based oncology clinics. Written informed consent was 
obtained from all patients. Study procedures were approved by the Committee on Human 
Research at the University of California, San Francisco and by each study site. Of the 2234 
patients approached, 1343 consented to participate (60.1%). Patients who completed all of the 
stress and resilience measures (n=957) were included in this analysis.  
Instruments 
Demographic and Clinical Characteristics - Patients completed a demographic questionnaire, 
the Karnofsky Performance Status (KPS) scale,24 and the Self-Administered Comorbidity 
Questionnaire (SCQ).25 Medical records were reviewed for disease and treatment information. 
Stress and Resilience Measures 
Perceived Stress Scale (PSS) - The 14-item PSS was used to assess global stress. 19 
Patients indicated the degree to which they perceived life circumstances as stressful over the 
previous week. Items were rated from 0 (never) to 4 (very often). Higher sum scores indicate 
greater perceived stress. The PSS has well established validity and reliability.19 In this current 
study, its Cronbach’s alpha was 0.89. 
Impact of Event Scale-Revised (IES-R) - The IES-R is a 22-item instrument that was 
used to measure distress associated with cancer and its treatment.20 Patients rated each item 
based on how distressing each potential difficulty was for them during the past week “with 
respect to their cancer and its treatment”. Each item was rated on a 0 to 4 Likert scale (i.e., 0 = 
not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, 4 = extremely). Three subscales were 
created using the mean of the responses. A total IES-R score was created by summing the 
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responses to the 22 items. The three subscales evaluate the levels of intrusion, avoidance, and 
hyperarousal perceived by a patient. The total IES-R score can range from 0 to 88. For the total 
IES-R score, a sum score of >24 indicates clinically meaningful post-traumatic symptomatology 
and scores of >33 indicate probable PTSD.26, 27 The IES-R has well established validity and 
reliability.26 In the current study, its Cronbach’s alpha was 0.92. 
Life Stressor Checklist-Revised (LSC-R) - The 30-item LSC-R was used to evaluate 
lifetime exposure to stressful life events.21 Patients indicated the occurrence of 30 stressors and 
rated the effect of each stressor on their past year of life, from 1 (not at all) to 5 (extremely). A 
higher number (i.e., count) of stressful life events and higher mean effect scores indicate greater 
stress exposure and impact, respectively. LSC-R demonstrates adequate test–retest reliability and 
criterion-related validity among diverse populations. 28, 29 
Connor-Davidson Resilience Scale (CD-RISC-10) - The 10-item CD-RISC-10 was used 
to measure resilience.22 Items were rated from 0 (not true at all) to 4 (true nearly all the time). 
Higher sum scores indicate greater resilience. CD-RISC-10 has adequate validity and reliability 
in diverse populations.22, 30 In the current study, its Cronbach’s alpha was 0.90. 
Symptom Measures 
Attentional Function Index (AFI) – The 16-item AFI was designed to measure attentional 
function.31 A higher total mean score on a 0 to 10 NRS indicates greater capacity to direct 
attention.31 Total scores are grouped into categories of attentional function (i.e., <5.0 low 
function, 5.0 to 7.5 moderate function, >7.5 high function).32 In addition, the AFI has three 
subscales (i.e., effective action, attentional lapses, interpersonal effectiveness). The AFI has well 
established reliability and validity.31 In this study, the Cronbach’s alpha for the total AFI score 
was 0.93. 
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General Sleep Disturbance Scale (GSDS) – The 21-item GSDS was designed to assess 
the quality of sleep in the past week.33 Each item was rated on a 0 (never) to 7 (everyday) NRS. 
The GSDS total score is the sum of the seven subscale scores that can range from 0 (no 
disturbance) to 147 (extreme sleep disturbance). Each mean subscale score can range from 0 to 
7. Higher total and subscale scores indicate higher levels of sleep disturbance. Subscales scores 
of >3 and a GSDS total score of >43 indicate a significant level of sleep disturbance.34 The 
GSDS has well-established validity and reliability.33, 35, 36 In the current study, the Cronbach’s 
alpha for the GSDS total score was 0.83. 
Lee Fatigue Scale (LFS) – The 18-item LFS is designed to assess physical fatigue and 
energy.37 Each item was rated on a 0 to 10 numeric rating scale (NRS). Total fatigue and energy 
scores are calculated as the mean of the 13 fatigue items and the 5 energy items, respectively. 
Higher scores indicate greater fatigue severity and higher levels of energy. Using separate LFS 
questionnaires, patients were asked to rate each item based on how they felt within 30 minutes of 
awakening (i.e., morning fatigue, morning energy) and prior to going to bed (i.e., evening 
fatigue, evening energy). The LFS has established cut-off scores for clinically meaningful levels 
of fatigue (i.e., ≥3.2 for morning fatigue, ≥5.6 for evening fatigue) (34) and energy (i.e., <6.2 for 
morning energy, <3.5 for evening energy).34 It was chosen for this study because it is relatively 
short, easy to administer, and has well established validity and reliability.36-41 In the current 
study, the Cronbach’s alphas were 0.96 for morning and 0.93 for evening fatigue and 0.95 for 
morning and 0.93 for evening energy. 
Data Analysis 
As described previously,18 LPA was used to identify subgroups (i.e., latent classes) of 
patients with distinct stress profiles, using patients’ scores on the stress (PSS, IES-R, LSC-R) 
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and resilience (CD-RISC-10) measures. LPA was conducted using MPlusTM Version 7.4.42 
Estimation was conducted using robust maximum likelihood and the expectation maximization 
algorithm. Statistical fit indices were used to determine the number of classes that best captured 
variability, while maintaining conceptual clarity.43, 44 
For this analysis, descriptive statistics and frequency distributions were calculated for 
demographic and clinical characteristics, stress and resilience scores, using SPSS version 26.45 
Analyses of variance, Kruskal-Wallis, or Chi-square analyses were used to evaluate for 
differences in demographic and clinical characteristics and symptom scores among the classes. A 
p-value of <0.05 were considered statistically significant. The Bonferroni correction was used for 
post hoc contrasts.  
Results 
Results of the LPA 
 The LPA identified three latent classes based on the stress and resilience measures.18 
Supplemental Table 1 displays the fit indices for the 1- through 4-class solutions. The 3-class 
solution was selected based on its lower Bayesian Information Criterion, higher entropy, and 
statistically significant Vuong-Lo-Mendell-Rubin, indicating the best fit. 
Of the entire sample, 382 patients (39.9%) were classified as “Stressed”, 520 patients 
(54.3%) as “Normative”, and 55 patients (5.7%) as “Resilient”. To name these classes (Table 1), 
mean stress and resilience scores were compared among the classes, as well as to established cut-
off scores26 and national normative data.22, 46 The latent classes differed significantly on all of the 
stress and resilience scores (all p<0.001). Post hoc contrasts revealed consistent patterns for 
global stress (i.e., PSS; Stressed > Normative > Resilient) and resilience (Stressed < Normative < 
Resilient). For occurrence of life stressors measured using the LSC-R, post hoc contrasts 
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revealed the following pattern: Stressed > Resilient > Normative. For cancer-related stress, 
Stressed patients reported higher IES-R total scores than Normative and Resilient patients (i.e., 
Stressed > Normative and Resilient).18  
Differences in Demographic and Clinical Characteristics 
 As shown in Supplemental Table 2,18 compared to Normative patients, Stressed patients 
were younger, more likely to be female, had fewer years of education, lower annual household 
incomes, and were less likely to be employed. Compared to Normative and Resilient classes, 
Stressed patients were more likely to be single and live alone.  
For clinical characteristics, functional status, comorbidities, as well as self-reported 
depression and back pain differed among the latent classes. Compared to Normative patients, 
Stressed patients reported a higher comorbidity burden and were more likely to report back pain. 
Compared to Normative and Resilient patients, Stressed patients had lower functional status 
scores and were more likely to report depression. Demographic and clinical characteristics did 
not differ between Normative and Resilient patients. Moreover, no disease or treatment 
characteristics differed among the classes. 
Differences in Symptom Severity Scores 
 As shown in Table 2, for attentional function, significant differences in the interpersonal 
effectiveness and total AFI scores were found among the latent classes (Stressed < Normative < 
Resilient). In addition, compared to the other two classes, patients in the stressed class had lower 
effective action and attentional lapses subscale scores. 
For sleep disturbance, as well as morning and evening fatigue, compared to the 
Normative and Resilient classes, patients in the Stressed class reported higher GSDS and LFS 
scores. For morning energy, compared to the Normative and Resilient classes, patients in the 
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Stressed class reported low scores. For evening energy, compared to the Normative class, 
patients in the Stressed class reported lower scores. 
Discussion 
This study is the first to evaluate for differences in fatigue, energy levels, sleep 
disturbance, and cognitive function in subgroups of patients with distinct stress profiles. Details 
on the differences among these subgroups in terms of their specific stress profiles, as well as 
demographic and clinical characteristics are described in our previous publication.18 The 
remainder of this discussion focuses on our findings related to differences among the subgroups 
in the severity of common physical symptoms associated with cancer and CTX administration.  
Consistent with our a priori hypothesis, patients in the Stressed class had the highest 
symptom severity scores for all four symptoms and all of these scores were above the clinically 
meaningful cutoffs for the various instruments. In contrast, while the stress and resilience scores 
differed between the Normative and Resilient classes, for most of the symptoms, no between 
group differences in symptom severity scores were found. This finding may be related to the 
relatively high symptom burden experienced by all three classes or the relatively small number 
of patients in the Resilient class. 
While numerous studies have investigated risk factors for CRCI during and following 
cancer treatment,47-50 the majority have evaluated for associations with demographic, clinical, 
and treatment characteristics using a variety of subjective and objective measures. In this study 
and consistent with previous reports,16 we provide additional evidence that a subgroup of 
oncology patients with high levels of general and disease-specific stress, as well as cumulative 
life stress have the worse decrements in cognitive function. While the total scores and the 
interpersonal effectiveness subscale scores of the AFI differentiated among the three classes, all 
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three subgroups had moderate decrements in cognitive function. The AFI evaluates patients’ 
perceptions of their effectiveness in carrying out basic activities of daily living that require 
focused attention; their perceived difficulties in directing attention on daily tasks, as well as their 
perceptions of their ability to interact in a deliberate manner that depends on selective attention.31 
Of note, in a recent functional MRI study, that evaluated patients with breast cancer undergoing 
CTX,51 decreases in AFI scores paralleled disruptions in resting-state BOLD functional 
connectivity in parietal and frontal brain regions. To confirm the previous observations that 
chronic stress effects the functioning of the PFC,14 future studies of CRCI should include both 
subjective and objective measures of cognitive function as well as multidimensional measures of 
stress. 
In terms sleep disturbance, while the three latent classes had total sleep disturbance 
scores about the clinically meaningful cutoff, patients in the Stressed class had scores that 
represent an extremely high level of sleep disturbance that is comparable to scores reported by 
shift workers (i.e., 60.5)33 and parents of newborn infants (55.5).38 In terms of the GSDS 
subscale scores, the high levels of mid-sleep and early awakenings suggest that all three classes 
have problems with sleep maintenance. Of note, for patients in the Stressed class, all of the 
GSDS subscale scores were above the clinically meaningful cutoff of >3 days per week. In 
particular, their score of 3.6 (+2.3) on the sleep onset latency subscale suggests that these 
patients have problems with both sleep initiation and maintenance. Again, our findings are 
consistent with the preclinical and human studies of the negative impact of stress on sleep.3, 11 
Previous research from our group has demonstrated that morning and evening fatigue are 
distinct but related symptoms.23, 52, 53 Based on the scores reported by our Stressed class, high 
levels of general and disease specific stress, as well as cumulative life stress are associated with 
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clinically meaningful levels of both morning and evening fatigue. While lack of energy and 
fatigue are used interchangeably in the symptom literature, a growing body of evidence suggests 
that energy and fatigue are distinct but related symptoms.54-56 While no studies have evaluated 
for associations between decrements in energy levels and stress, while our Stressed class 
reported decrements in both morning and evening energy levels, the other two classes reported 
morning energy levels that were well below the clinically meaningful cutoff of <6.2. These 
findings may be related to the relatively high levels of sleep disturbance in all three classes and 
warrant confirmation in future studies. 
Consistent with our a priori hypothesis, patients in the Stressed class reported the highest 
level of symptom burden. Of note, the patients in this subgroup (i.e., 41% of the sample) 
reported clinically meaningful levels of all four of these co-occurring symptom. This extremely 
high risk group was younger, more likely to be female, had a lower socioeconomic status, was 
not married or partnered, was more likely to live alone, had a poorer functional status, and a 
worse comorbidity profile (see Supplementary Table 2).18 These high risk patients warrant 
ongoing assessments of both stress and symptom burden. 
While this study has several limitations, it provides directions for future research. While 
the sample was heterogeneous in terms of cancer diagnoses and CTX regimens, it was fairly 
homogenous in terms of gender, educational level, and ethnicity. Given that the stress measures 
were done only once, changes in the severity of stress and symptoms could not be evaluated. 
Future longitudinal studies, that use analytic techniques like parallel process growth modeling,57 
will be able to discern the causal relationships between stress and symptom burden. While recent 
investigations in symptoms science are focused on an evaluation of multiple co-occurring 
symptoms and symptom clusters in oncology patients and patients with other chronic conditions, 
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58, 59 as noted in the introduction to this paper, the limited amount of research has focused on an 
examination of the relationships between stress and single symptoms. Given the findings from 
this study, careful consideration should be given to an evaluation of not only general, disease-
specific, and cumulative life stress but multiple co-occurring symptoms in patients with cancer 
and other chronic conditions. These types of studies that include both subjective and objective 
measures, as well as biomarkers will increase our knowledge of the fundamental mechanisms 
that underlie the relationships between stress and symptoms. 
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Supplemental Table 1 - Latent Profile Solutions and Fit Indices for One Through Four Class 
Solutions  
Model LL AIC BIC Entropy VLMR 
1 Class -3607.97 7243.93 7312.03 n/a n/a 
2 Class -3446.31 6950.63 7091.68 .56 323.31**** 
3 Classa -3390.00 6868.01 7082.01 .73 112.62**** 
4 Class -3349.51 6817.02 7103.98 .65 80.99ns 
 
**** p < .0001 
 
a The three class solution was selected because the BIC for that solution was lower than the BIC for 
both the 2- and 4-class solutions. In addition, the VLMR was significant for the 3-class solution, 
indicating that three classes fit the data better than two classes. The VLMR was not significant for 
the 4-class solution, indicating that too many classes had been extracted. 
 
Abbreviations: AIC = Akaike’s Information Criterion; BIC = Bayesian Information Criterion; LL = 
log-likelihood; n/a = not applicable, ns = not significant; VLMR = Vuong-Lo-Mendell-Rubin 
likelihood ratio test for the K vs. K-1 model. 
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